Clinical Outcome and Prognostic Factors of Biopsy-proven Diffuse Proliferative Lupus Nephritis.
- Author:
Hyun Yong SONG
1
;
Jae Ha HWANG
;
Hyun Jung ROH
;
Dong Ryeol RYU
;
Tae Hyun YOO
;
Young Su SONG
;
Joo Seong KIM
;
Hyun Jin NOH
;
Suk Kyun SHIN
;
Chan Hee LEE
;
Kyun Hun CHOI
;
Soo Kon LEE
;
Sung Kyu HA
;
Ho Yung LEE
;
Dae Suk HAN
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Korea. khchoi6@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Diffuse proliferative lupus nephritis;
Prognostic factor;
Treatment moda-lity;
Outcome
- MeSH:
Academic Medical Centers;
Biopsy;
Creatinine;
Cyclophosphamide;
Diagnosis;
Follow-Up Studies;
Humans;
Lupus Nephritis*;
Medical Records;
Mortality;
Nephritis;
Prognosis;
Proteinuria;
Survival Rate
- From:Korean Journal of Nephrology
2000;19(1):83-90
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lupus nephritis is a major cause of morbidity and mortality arising from systemic lupus erythematous. It is generally acknowledged that the presence of diffuse proliferative lupus nephritis(DPLN) is highly predictive of a poor prognosis in terms of renal and patient out- come on survival. The objective of this study was to evaluate the clinicopathologic characteristics, renal out- come according to therapeutic regimen, and prognostic factors of biopsy-proven diffuse proliferative lupus nephritis. Among the biopsy-proven lupus nephritis patients who were admitted to Yonsei University Medical Center from January 1986 to June 1997, 36 patents who were diagnosed DPLN by renal biopsy and treated for at least 6 months and regularly followed-up for at least 12 months were included. We retrospec-tively reviewed the medical recorders. Patients were treated with steroid regimen with or without cyclo-phosphamide. According to the therapeutic response, patients were divided into two groups : a therapeutic response group(n=24), and a therapeutic non-response group
